v3.26.1
Segments - Schedule of Drug Development Segment and Reconciliation to Consolidated Net Income (Loss) Segment Operations (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]        
Total revenue $ 235 $ 1,364 $ 235 $ 1,620
Clinical expense 2,019 2,506 4,036 4,217
Preclinical expense 189 1,032 434 1,969
Chemistry, manufacturing, and controls 138 1,771 692 2,273
IPR&D expense 3,891 7,141 16,243 12,282
Selling, general and administrative 4,119 3,784 8,707 7,528
Interest expense 0 0 0 173
Interest income (685) (510) (1,168) (1,305)
Other segment expense (income) [1] (12,942) (334) (6,564) (959)
Segment net income (loss) 7,397 (6,885) (13,902) (12,276)
Adjustments and reconciling items 0 0 0 0
Net income (loss) 7,397 (6,885) (13,902) (12,276)
In process research and development        
Segment Reporting Information [Line Items]        
IPR&D expense $ 0 $ 0 $ 8,000 $ 0
[1] Other segment expense (income) includes other research and development expense, amortization of debt issuance costs and discount, other income, and the warrant liabilities fair value adjustment.